Welcome to our dedicated page for Koru Med Sys news (Ticker: KRMD), a resource for investors and traders seeking the latest updates and insights on Koru Med Sys stock.
KORU Medical Systems, Inc. (NASDAQ: KRMD) is a medical technology company in the surgical and medical instrument manufacturing industry, focused on large-volume subcutaneous infusion solutions. News about KORU Medical frequently centers on its Freedom Syringe Infusion System, financial performance, regulatory milestones, and collaborations with biopharmaceutical partners.
Investors following KRMD news can expect regular updates on quarterly and annual financial results, including net revenue trends, core business performance, and contributions from Pharma Services and Clinical Trials. The company often provides revenue guidance and discusses metrics such as gross margin and cash position in its earnings-related press releases, which are also referenced in Form 8-K filings.
KORU Medical’s news flow also highlights regulatory and clinical developments. This includes FDA 510(k) submissions for the Freedom System to be used with specific biologic drugs, such as rare disease therapies and oncology biologics like PHESGO for HER2+ breast cancer. The company reports clinical and real-world evidence, including multicenter evaluations comparing the FreedomEdge Infusion System with manual push techniques in oncology and immunology settings, focusing on nurse satisfaction, patient comfort, and workflow efficiency.
Another key news category involves strategic collaborations and development agreements with pharmaceutical and medical technology partners. Examples include agreements to develop next-generation subcutaneous immunoglobulin infusion systems and to integrate the FreedomEdge pump into wearable infusion platforms for targeted antibiotic delivery in periprosthetic joint infection.
In addition, KORU Medical issues announcements about leadership appointments, equity awards, and participation in investor conferences, providing insight into its management priorities and engagement with the investment community. For ongoing coverage of KRMD, this news page aggregates company press releases and related updates so readers can monitor financial disclosures, regulatory progress, and partnership activity over time.
KORU Medical (NASDAQ: KRMD) will participate in three investor conferences in Nov–Dec 2025. Management will attend the 16th Annual Craig‑Hallum Alpha Select Conference on Nov 18, 2025, the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Nov 20, 2025, and will present at Piper Sandler’s 37th Annual Healthcare Conference on Dec 2, 2025 at 9:30 am ET. Interested parties can access live and archived webcasts on the company’s Investors > News/Events page at www.korumedical.com.
KORU Medical Systems (NASDAQ: KRMD) announced a development agreement with a global pharmaceutical company to collaborate on next‑generation subcutaneous immunoglobulin (SCIg) infusion systems.
The work will support qualification of an infusion system that accepts both vials and prefilled syringes (PFS), built on KORU’s Freedom60®/FreedomEDGE® infusion technology and SCHOTT TOPPAC® polymer syringes. KORU highlights its FREEDOM Syringe Infusion System as supporting 5mL–50mL+ volumes and being market proven with 15+ years of home use, 45,000+ patients, 2M+ infusions annually, a 97% adherence rate, 8 on‑label subcutaneous drugs, and distribution in 30+ countries.
KORU Medical Systems (NASDAQ: KRMD) will report its third quarter 2025 financial results on Wednesday, November 12, 2025.
Management will host a conference call and live webcast at 4:30 p.m. ET to discuss results and provide a corporate update. U.S./Canada dial-in is (877) 407-0784; international dial-in is (201) 689-8560. A live and archived webcast will be available via the Investor Relations calendar at www.korumedical.com. The archived webcast will remain accessible for six months.
KORU Medical Systems (NASDAQ: KRMD) has partnered with ForCast Orthopedics to integrate KORU's FreedomEDGE® infusion system into ForCast's Wearable Intra-Articular Infusion System (WIIS) for treating periprosthetic joint infection (PJI).
The collaboration aims to support ForCast's FC001 program, which has received both Orphan Drug Designation and Qualified Infectious Disease Program (QIDP) designation from the FDA. The program targets PJI, a rare but serious complication of joint replacement procedures where bacteria form resistant biofilms on prostheses. Clinical trials are anticipated to begin in 2026.
KORU Medical Systems (NASDAQ: KRMD) reported strong Q2 2025 financial results, achieving a significant milestone with quarterly revenue exceeding $10.2 million, marking a 21% increase year-over-year. The company's core business revenue grew 19% to $9.3 million, while Pharma Services and Clinical Trials revenue surged 42% to $0.9 million.
Key highlights include gross profit of $6.5 million (63.5% margin), improved cash position with quarterly usage of $0.6 million, and the appointment of Adam Kalbermatten as Chief Commercial Officer. The company raised its 2025 revenue guidance to $39.5-$40.5 million, representing 18-20% growth, while maintaining gross margin guidance of 61-63%.
Notable developments include the Freedom Infusion System's expanded indication for Empaveli® in C3G and Primary IC-MPGN treatment, and a new FDA 510(k) submission for use with a rare disease biologic drug.
KORU Medical Systems (NASDAQ: KRMD), a medical technology company specializing in subcutaneous infusion solutions, has granted inducement equity awards to its new Chief Commercial Officer, Adam Kalbermatten. The compensation package includes:
600,000 nonqualified stock options at $3.44 per share granted on August 1, 2025, and 300,000 restricted shares awarded on July 28, 2025. Both awards vest 25% annually over four years, with potential accelerated vesting. The Compensation Committee approved these awards under Nasdaq Listing Rule 5635(c)(4) as part of Kalbermatten's employment agreement dated June 30, 2025.
KORU Medical Systems (NASDAQ: KRMD), a medical technology company specializing in subcutaneous infusion solutions, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference.
The Company's management will deliver their presentation on August 13, 2025, at 10:30 am ET. Investors and interested parties can access both the live and archived webcast through the News/Events page in the Investors section of KORU Medical's website.
KORU Medical Systems (NASDAQ: KRMD), a medical technology company specializing in subcutaneous infusion solutions, has scheduled its second quarter 2025 financial results announcement for August 6, 2025.
The company will host a conference call and webcast at 4:30 p.m. ET on the same day. U.S. and Canadian participants can dial (877)-407-0784, while international callers should use (201)-689-8560. The webcast will be available on KORU Medical's investor relations website for six months following the event.
KORU Medical Systems (NASDAQ: KRMD) has appointed Adam Kalbermatten as Chief Commercial Officer, effective July 28, 2025. Kalbermatten brings over 20 years of commercial leadership experience in medical devices and pharmaceuticals, joining from Becton Dickinson where he served as VP and GM of Advanced Drug Delivery Systems.
In his new role, Kalbermatten will oversee KORU Medical's global commercial strategy, including marketing, sales, market access, and pharmaceutical customer engagement. His previous experience includes serving as CEO of ZebraSci and holding global leadership positions at Terumo Medical Corporation. He holds engineering degrees from Stevens Institute of Technology and an MBA from Columbia Business School.